All In Biotech

Drug Trial Radar · NCT07830212

Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study

A Study to Evaluate the Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Yong HeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the diagnostic performance of \[68Ga\]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected recurrence after treatment. The study will assess the ability of this imaging to detect lesions and its diagnostic performance, including sensitivity, specificity, and accuracy. Histopathology and/or clinical follow-up of at least 6 months will be used as the reference standard. Participants will receive a single intravenous injection of \[68Ga\]Ga-OncoACP3 and undergo a PET/CT scan about 1 hour later. For participants who have already undergone clinically routine PSMA PET imaging, a comparison between the two imaging modalities will be performed. The study will enroll 50 men aged 18 to 90 years. Additionally, the study will explore the correlation between semi-quantitative parameters derived from \[68Ga\]Ga-OncoACP3 PET imaging and pathological markers (ACP3 expression assessed by immunohistochemistry in tumor tissue), and will evaluate the impact of \[68Ga\]Ga-OncoACP3 PET imaging on clinical treatment decisions.

Conditions

  • Prostatic Neoplasms
  • Prostate Cancer

Interventions

  • [68Ga]Ga-OncoACP3Drug

    \[68Ga\]Ga-OncoACP3 is a small-molecule PET imaging agent targeting ACP3 (prostate acid phosphatase). It is radiolabeled with Gallium-68 and administered as a single intravenous dose of 3-5 mCi. PET/CT imaging is performed at about 1 hour post-injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lesion Detection Rate of [68Ga]Ga-OncoACP3 PET ImagingTime frame: Up to 6 months after [68Ga]Ga-OncoACP3 PET imaging
  2. Sensitivity of [68Ga]Ga-OncoACP3 PET ImagingTime frame: Up to 6 months after [68Ga]Ga-OncoACP3 PET imaging
  3. Specificity of [68Ga]Ga-OncoACP3 PET ImagingTime frame: Up to 6 months after [68Ga]Ga-OncoACP3 PET imaging
  4. Accuracy of [68Ga]Ga-OncoACP3 PET ImagingTime frame: Up to 6 months after [68Ga]Ga-OncoACP3 PET imaging

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.